TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19485592
Drug: Family-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based cognitive-behavioral treatment (FCBT; N = 47) with exposure tasks
Study: 16820589
Drug: Statin (pravastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin (pravastatin 40 mg/d)
Study: 16820589
Drug: AT1 blockade
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT1 blockade (irbesartan 150 mg/d)
Study: 16820589
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of statin and AT1 blocker (same dosages)
Study: 16820589
Drug: Statin, AT1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin, AT1 blocker, and their combination
Study: 12759324
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with hormone replacement (conjugated equine estrogen, 0.625 mg/d, with or without medroxyprogesterone, 2.5 mg/d) and alendronate (10 mg daily)
Study: 12759324
Drug: Alendronate alone
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate alone (10 mg daily)
Study: 15240611
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy alone
Study: 12759324
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with hormone replacement and alendronate
Study: 12759324
Drug: All therapies
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All therapies (combination, alendronate, hormone replacement)
Study: 9117313
Drug: Proctolog (trimebutine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proctolog (trimebutine suppository) applied immediately after haemorrhoidectomy
Study: 9117313
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no suppository)
Study: 2445114
Drug: no anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: no anticoagulant treatment (control)
Study: 16200817
Drug: Fexofenadine, 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine, 180 mg once daily, with fluticasone propionate‐salmeterol, 250 microg twice daily
Study: 16200817
Drug: Placebo, with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, with fluticasone propionate‐salmeterol, 250 microg twice daily
Study: 16200817
Drug: Fexofenadine, 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine, 180 mg once daily, with fluticasone propionate alone, 250 microg twice daily
Study: 16200817
Drug: Placebo, with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, with fluticasone propionate alone, 250 microg twice daily
Study: 12742470
Drug: Full-dose cyclosporine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose cyclosporine, fixed-dose sirolimus, and corticosteroids
Study: 12742470
Drug: Reduced-dose cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-dose cyclosporine and trough concentration controlled sirolimus with corticosteroids
Study: 12742470
Drug: Sirolimus and
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus and steroids without calcineurin inhibitors
Study: 9862578
Drug: Cathepsin D
Normalized name: Cathepsin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cathepsin D positivity in oestrogen receptor-positive cases (57%)
Study: 23103596
Drug: Tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol hydrochloride 50 mg
Study: 23103596
Drug: Tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol hydrochloride 100 mg
Study: 23103596
Drug: Placebo (starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch tablet)
Study: 19944891
Drug: Azithromycin extended
Normalized name: azithromycin Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin extended release (2-g single dose)
Study: 19944891
Drug: Amoxicillin/clavulanate (875
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (875 mg/125 mg every 12 hours for 10 days)
Study: 21576440
Drug: Ertapenem 1
Normalized name: ertapenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem 1 g once daily
Study: 2343722
Drug: droperidol 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: droperidol 0.075 mg/kg
Study: 2343722
Drug: dixyrazine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: dixyrazine 0.25 mg/kg
Study: 7429342
Drug: Cimetidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (20 mg/kg body weight/24 h)
Study: 7429342
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (15 g/m2/24 h)
Study: 7429342
Drug: Pancreatic supplement
Normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic supplement (Pancrelipase, 27 capsules per day)
Study: 7429342
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cimetidine and sodium bicarbonate
Study: 31594719
Drug: Microdose (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdose (100 μg) of atorvastatin
Study: 31594719
Drug: Therapeutic dose
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic dose (10 mg) of atorvastatin
Study: 25583256
Drug: C1-esterase-inhibitor (C1-INH)
Normalized name: C1 esterase inhibitor
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1-esterase-inhibitor (C1-INH) administered at 1,000 international units (IU) intravenously
Study: 25583256
Drug: Corticosteroids and
Normalized name: Corticosteroids and mydriatics in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids and antihistamines (historical control)
Study: 24164846
Drug: Sesame group
Normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sesame group (40 g/day sesame by oral administration for 2 months)
Study: 7995010
Drug: 7-day nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day nicorandil (10 mg orally twice a day)
Study: 7995010
Drug: 7-day intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day intermittent nitroglycerin patch (10 mg for 16 of 24 hours)
Study: 2662829
Drug: Ketanserin 80
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 80 mg/day
Study: 2662829
Drug: Pentoxiphylline 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxiphylline 1,200 mg/day
Study: 29939049
Drug: Interim buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interim buprenorphine treatment (IBT; n = 25)
Study: 26682747
Drug: GH(67) 67
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH(67) 67 μg/kg/day (once daily)
Study: 26682747
Drug: GH(33) 33
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH(33) 33 μg/kg/day (once daily)
Study: 26682747
Drug: GH(33x2) 33
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH(33x2) 33 μg/kg/day (divided into two daily injections)
Study: 21575292
Drug: 2EHRZ/6HE regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2EHRZ/6HE regimen (daily EMB, INH, RMP, and PZA for 2 months, followed by EMB+INH for 6 months)
Study: 21575292
Drug: 2(EHRZ)(3)/6HE regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2(EHRZ)(3)/6HE regimen (same drugs in the intensive phase but given three times weekly, followed by daily EMB+INH for 6 months)
Study: 21575292
Drug: 2EHRZ/4HR regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2EHRZ/4HR regimen (same intensive phase as in regimen 1, followed by 4 months of daily RMP+INH)
Study: 18291010
Drug: Traditional medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional medicine as first-line treatment
Study: 11022777
Drug: Subantimicrobial dose
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subantimicrobial dose doxycycline (SDD), 20 mg bid
Study: 1611143
Drug: Cyclosporine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (10 mg/kg/day, single daily dose)
Study: 31623621
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of firocoxib and PCSO-524
Study: 26654115
Drug: CIT-S (Culturally
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIT-S (Culturally Informed Therapy)
Study: 22571902
Drug: Low-dose peginterferon-alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose peginterferon-alfa-2a (PEG-IFN)
Study: 19799627
Drug: hydroxyurea and
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydroxyurea and l-carnitine
Study: 19799627
Drug: hydroxyurea, l-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydroxyurea, l-carnitine and magnesium chloride
Study: 16261883
Drug: Defibrase 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrase 15 U plus normal saline 250 mL, followed by defibrase 5 U on days 3, 5, 7, and 9
Study: 9617677
Drug: Allogenic bone
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogenic bone implants (ABI)
Study: 28703950
Drug: Internet-based psychoeducation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based psychoeducation treatment group (n = 40)
Study: 28430015
Drug: Mindfulness and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness and acceptance group therapy
Study: 15138428
Drug: Misoprostol (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (active drug)
Study: 10623692
Drug: Filgrastim or
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim or sequential regimen
Study: 9369134
Drug: Etanidazole (Eta)
Normalized name: Tinidazole
DrugBank: Etanidazole (DB12736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etanidazole (Eta) with dose and schedule adjustment
Study: 9369134
Drug: Conventional radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional radiation therapy (RT) alone
Study: 2412042
Drug: Beta‐adrenergic blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta‐adrenergic blockers alone
Study: 18487480
Drug: Fenofibrate 160
Normalized name: fenofibrate 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 160 mg daily
Study: 18487480
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 200 mg daily
Study: 18487480
Drug: Fenofibrate 160
Normalized name: fenofibrate 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 160 mg plus CoQ 200 mg daily
Study: 8931744
Drug: Cytarabine 500
Normalized name: CYTARABINE 500MG/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytarabine 500 mg/m2 0 h and 12 h, cisplatin 15 mg/m2 6 h and 18 h. Day 2‐4: cisplatin 30 mg/m2. Cycles repeated every 4 weeks
Study: 1880233
Drug: Estazolam 1
Normalized name: estazolam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estazolam 1 mg
Study: 1880233
Drug: Estazolam 2
Normalized name: estazolam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estazolam 2 mg and Flurazepam 30 mg
Study: 7068093
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of chlorhexidine, tramazoline and aluminiumtrilactate (n = 50)
Study: 31470879
Drug: Phlebotomy (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlebotomy (450 mL of whole blood venesection)
Study: 31470879
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (OCs) containing cyproterone acetate (3 months treatment)
Study: 27842470
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care intervention (delivered by social workers without previous mental health experience, including cognitive-behavioral therapy or facilitated antidepressant medication)
Study: 21742514
Drug: Turmeric supplementation
Normalized name: Turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmeric supplementation (500 mg turmeric, 22.1 mg curcumin, 3 capsules daily for 3 months)
Study: 21742514
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (starch, identical in color and size to turmeric capsules, 3 capsules daily for 3 months)
Study: 25151662
Drug: Treatment interventions
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment interventions
Study: 15798291
Drug: R(int) measured
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R(int) measured at flows <0.3 l s(‐1)
Study: 12939120
Drug: Chitosan formulation
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan formulation (2100 mg chitosan and 300 mg psyllium husk seeds, six capsules three times daily for three days)
Study: 9583342
Drug: Preparing for
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparing for the Drug‐Free Years Program (PDFY)
Study: 1854051
Drug: Adenosine triphosphate
Normalized name: Adenosine triphosphate
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine triphosphate (ATP) at doses of 0.012, 0.025, and 0.05 mg.kg‐1.min‐1
Study: 6344732
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of subcuticular suture and sterile Micropore tape
Study: 29870591
Drug: Amenamevir 400
Normalized name: amenamevir
DrugBank: Amenamevir (DB11701)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Amenamevir 400 mg with montelukast 10 mg
Study: 29870591
Drug: Amenamevir 400
Normalized name: amenamevir
DrugBank: Amenamevir (DB11701)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Amenamevir 400 mg with bupropion 150 mg
Study: 21194357
Drug: Sitagliptin (DPPIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (DPPIV inhibitor)
Study: 18651257
Drug: MR arthrography
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR arthrography with Gd-DTPA2- injection and comprehensive imaging (static and dynamic)
Study: 17050788
Drug: Varenicline 1
Normalized name: varenicline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 1 mg once daily for 7 days (n = 8)
Study: 17050788
Drug: Varenicline 1
Normalized name: varenicline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 1 mg twice daily for 6 days with a single dose on day 7 (n = 8)
Study: 15727187
Drug: Multiplex nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiplex nutritional intervention group (100 g coarse food grain every day and nutrition education)
Study: 11004017
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of L-arginine and GHRP-2 (AG)
Study: 1346342
Drug: Control (triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (triple therapy without amiodarone)
Study: 6088192
Drug: Standard meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard meal with 12 g olive oil
Study: 6088192
Drug: Standard meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard meal with 36 g olive oil
Study: 29427024
Drug: linagliptin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin (5 mg, once-daily)
Study: 29427024
Drug: voglibose (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: voglibose (0.9 mg, thrice-daily)
Study: 12149667
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Trandolapril 0.5 mg/day + Irbesartan 150 mg/day)
Study: 9539500
Drug: Abciximab (platelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abciximab (platelet glycoprotein IIb/IIIa inhibitor)
Study: 9539500
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (control group not explicitly mentioned)
Study: 337478
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of glycerol (25 g twice daily for 6 days)
Study: 21684508
Drug: Aspirin 50
Normalized name: aspirin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 50 mg or 100 mg
Study: 11334905
Drug: 5% saline
Normalized name: Breathe Free 0.65% Saline Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% saline infusion on day 3 or 4 after hCG administration in IVF patients
Study: 11334905
Drug: 5% saline
Normalized name: Breathe Free 0.65% Saline Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% saline infusion test on day 10 after hCG administration
Study: 11334905
Drug: 5% saline
Normalized name: Breathe Free 0.65% Saline Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% saline infusion in controls (normal menstrual cycles)
Study: 3668801
Drug: intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion
Study: 3668801
Drug: oral capsules
Normalized name: Plenity Oral Capsules
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral capsules
Study: 25544247
Drug: Sufentanil 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 15 μg sublingual tablet (SL) administered using the SSTS system
Study: 25544247
Drug: Sufentanil 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 15 μg sublingual tablet (SL) administered using the SSTS system (40 consecutive doses)
Study: 25544247
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration of sufentanil
Study: 25544247
Drug: Sufentanil buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil buccal (BU) administration
Study: 25544247
Drug: Sufentanil oral
Normalized name: SUFentanil Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil oral (PO) administration
Study: 25544247
Drug: Sufentanil sublingual
Normalized name: SUFentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil sublingual (SL) administration
Study: 22855038
Drug: Total glucosides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total glucosides of paeony capsule (TGPC), 600 mg per time, three times daily for three months
Study: 22855038
Drug: Compound glycyrrhizin
Normalized name: glycyrrhizinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound glycyrrhizin tablet, 50 mg per time, three times daily for three months
Study: 20798432
Drug: Stopping antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopping antiplatelet agents
Study: 20798432
Drug: Traditional approach
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional approach of stopping medications up to two weeks before surgery
Study: 2201721
Drug: Zopiclone 7.5
Normalized name: zopiclone 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone 7.5 mg or higher
Study: 6669631
Drug: Zopiclone 11.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone 11.25 mg
Study: 2201721
Drug: Zopiclone 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone 3.5 mg and 7.5 mg
Study: 2201721
Drug: Zopiclone up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone up to 11.25 mg
Study: 2201721
Drug: Zopiclone higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone higher doses when well tolerated
Study: 29020150
Drug: Ceftriaxone (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1.0 g, intravenously, once daily for 10 days)
Study: 29020150
Drug: Benzathine Penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine Penicillin G (2.4 million units, intramuscularly, once weekly for 2 weeks)
Study: 29020150
Drug: Benzathine Penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine Penicillin G
Study: 15208051
Drug: Mifepristone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 10 mg weekly
Study: 15208051
Drug: Mifepristone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 10 mg planned postcoitally
Study: 9272610
Drug: Therapies that
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapies that lower glucose levels
Study: 30947737
Drug: Intervention practices
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention practices received £1500, a support manual, and four meetings to develop local solutions.
Study: 16729880
Drug: Joint mobilisation
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint mobilisation twice a week for four weeks
Study: 9159724
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment for 10 weeks